Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin CA91911K1021
Ticker VRX
Currency $
Aware Investor Index (AII) 0.0000
Recommendation STRONG SELL
P/E 239.46
ROE 1.20 %
Capitalization 15,616,795,000 $
Dividend Yield 0.00 %
P/S 1.89
AII Position 776
P/E Position 766
ROE Position 779
Capitalization Position 415
Dividend Yield Position 629
Sales 8,263,500,000 $
10-Year Average Earnings 65,217,000 $
Shares Outstanding 341,500,000
Equity 5,434,500,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country Canada
VALEANT PHARMACEUTICALS INTERNATIONAL Investor Relations Web Site http://ir.valeant.com


2014 12 8,263,500,000.00 $
2013 12 5,769,605,000.00 $


2014 12 913,500,000.00 $
2013 12 -866,142,000.00 $
2012 12 -116,025,000.00 $
2011 12 159,559,000.00 $
2010 12 -208,193,000.00 $
2009 12 176,455,000.00 $
2008 12 199,904,000.00 $
2007 12 103,541,000.00 $
2006 12 228,939,000.00 $
2005 12 60,632,000.00 $


2014 12 5,434,500,000.00 $
2013 12 5,233,322,000.00 $
2012 12 3,717,398,000.00 $

Shares Outstanding:

2014 12 341,500,000
2013 12 320,996,000
2012 12 303,861,000



Jan 3, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1368 SSO PROSHARES U SSO US 01/22/11 C40 16.9 53.7 9.27 14.4 517 VRX VALEANT PHA VRX US 01/22/11 C26 16.8 47.4 3.05 -7.6 1000 CSCO CISCO SYSTE CSCO US 01/22/11...
Jan 6, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1500 CVE CENOVUS ENE CVE US 03/19/11 C22.5 17.3 55.9 10.30 -5.5 500 VRX VALEANT PHA VRX US 01/22/11 C32 17.1 38.9 3.30 407.7 1291 CSX CSX CORP CSX US 01/22/11...
Dec 1, 2003
A New Way To Fight Hepatitis C
better at bypassing the blood cells and going straight to the liver. Valeant Pharmaceuticals (VRX), formerly ICN Pharma-ceuticals (ICN), developed both drugs. And it announced in early November...
Feb 27, 2006
In India, Selling Generics Used To Be So Easy
Jersey, and bought an Ohio factory from California-based Valeant Pharmaceuticals International (VRX ). In December, Bombay's Glenmark Pharmaceuticals announced a deal with InvaGen Pharmaceuticals...
Oct 2, 2008
North and South American Stock Rating Changes, New Coverage
-------------------------------------------------------------------------------- Valeant Pharmaceuticals Inte (VRX US) Matrix/Lighthouse Analyst Recommendation Action Target Team Coverage...
Feb 15, 2011
ValueAct Holdings Largest Holdings in 4th Qtr: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 762,695,599 26,959,901 Sara Lee Corp SLE US 611,428...
Feb 14, 2011
Brahman Capital Corp Largest Holdings in 4th Quarter: 13F Alert
Technologies Holding ST US 70,728,842 2,349,015 2,349,015 Valeant Pharmaceuticals Inte VRX US 65,248,056 2,306,400 -254,700 Xerox Corp XRX US 57,273...
Nov 10, 2011
Zweig Dimenna Partners Holdings in 3rd Quarter: 13F Alert
Freeport-McMoRan Copper FCX US -21,681,938 173,360 -336,295 Valeant Pharmaceuticals Inte VRX US -20,560,233 124,345 -360,180 Williams Cos Inc WMB US -17,574...
Sep 28, 2011
Allon, PetroAmerica, Rare Element, TMX: Canadian Equity Preview
offered to buy TMX for C$3.73 billion ($3.65 billion). Valeant Pharmaceuticals International Inc. (VRX CN): The drugmaker received approval for colesevelam hydrochloride, a treatment to help lower LDL...
Aug 4, 2011
Iridian Asset Mgmt Holdings in 2nd Quarter: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 295,603,506 5,689,059 -1,052,171 Wyndham Worldwide Corp WYN US 274,946...


The Ledger Gazette - 3 hours ago
Vetr Upgrades Valeant Pharmaceuticals International (VRX) to ...
Valeant Pharmaceuticals International logo Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday, December 5th. The brokerage currently has a $19.72 price ...
Valeant Pharma's (VRX) Bausch + Lomb Begins Distribution Of ...
Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that it has begun distributing VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% to U.S. wholesale ...
The Stock Street (press release)
Valeant: Perfect Time For An Equity Raise?
VRX has engaged in asset sales and debt refinancings but its credit metrics have not improved much. It recently filed an application to raise additional capital. The recent spike in the stock could be the perfect time for an equity raise. Sell VRX as short covering wanes or due to the risk of a dilutive event.
Concord Register
Valeant Pharmaceuticals International, Inc. (VRX)- Stocks having ...
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) belongs to Healthcare sector, other than individual factors many other macro and micro factors also effects whole sector and industries. Expecting these factors, the firm is standing on a contradictory position. To cut down amount of noise on price ...
StreetInsider.com - 3 hours ago
Tuesday's Vital Data: Tesla Inc (TSLA), Apple Inc. (AAPL) and ...
Tuesday's Vital Data: Tesla Inc (TSLA), Apple Inc. (AAPL) and Valeant Pharmaceuticals International, Inc. (VRX). Joseph Hargett. InvestorPlace December 12, 2017. Reblog. Share. Tweet. Share. U.S. stock futures are trending cautiously higher this morning, as focus remains on the Federal Reserve and the central bank's ...
Valeant: What Debt Problem?
Valeant Pharmaceuticals International Inc. (VRX) recently launched and priced an upsized unsecured note offering due in 2025. The offering was boosted to $1.5 billion from an original offering of $1 billion with a rate of 9%. The proceeds of the offering will primarily be used to pay down 7% senior notes ...
Seeking Alpha - 1 hour ago
Tracking Technical Indicators on Valeant Pharmaceuticals ...
Technical analysis of Valeant Pharmaceuticals International, Inc. (VRX) stock includes the study of technical indicators and past trends. For technical analysis of stock and trends here we employ the use of tools such as trading volumes, Simple Moving averages, RSI (14), and ATR (14) to determine the ...
NASDAQ Times - 1 hour ago
Valeant Pharmaceuticals International (VRX) PT Set at $18.00 by ...
Valeant Pharmaceuticals International, Inc. logo Deutsche Bank set a $18.00 price target on Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) in a research report report published on Sunday, December 3rd. The brokerage currently has a hold rating on the specialty pharmaceutical company's ...
Yahoo News - 6 days ago
CANADA STOCKS-TSX jumps, led by banks, energy stocks, Valeant ...
CANADA STOCKS-TSX jumps, led by banks, energy stocks, Valeant (VRX) ... Canada's main stock index gained in a broad rally in early trade on Monday, led by big banks and energy companies as well as Valeant Pharmaceuticals International Inc, which said it was bringing an eye treatment to market.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) – Brief ...
Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) closed the previous trading session at $19.71, experiencing a change of 0.15% with 23,766,588 shares trading hands. The stock holds an average trading capacity of 16.04M shares for the past three months. When we compare its current ...